Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factor

Background. Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD). In addition, CKD itself is a coronary artery disease equivalent due to its atherogenic potential. Despite the role of CKD in ASCVD and recommenda...

Full description

Saved in:
Bibliographic Details
Main Authors: M R Essop, F Seedat, F J Raal
Format: Article
Language:English
Published: South African Medical Association 2023-11-01
Series:South African Medical Journal
Subjects:
Online Access:https://samajournals.co.za/index.php/samj/article/view/1089
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860483559522304
author M R Essop
F Seedat
F J Raal
author_facet M R Essop
F Seedat
F J Raal
author_sort M R Essop
collection DOAJ
description Background. Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD). In addition, CKD itself is a coronary artery disease equivalent due to its atherogenic potential. Despite the role of CKD in ASCVD and recommendations to control lipid levels aggressively, landmark lipid studies have often excluded patients with advanced CKD. Furthermore, there is a scarcity of data on the use and efficacy of lipid-lowering therapy (LLT) in those with CKD in South Africa (SA). Objectives. To determine the prevalence and control of dyslipidaemia in a cohort of SA patients with CKD. Methods. A retrospective, cross-sectional observational study of 250 patients with CKD attending the Charlotte Maxeke Johannesburg Academic Hospital renal clinic from 1 July 2019 to 31 July 2020 was carried out. Lipograms, the use of LLT and achievement of target lipid levels were examined. Results. The median (interquartile range) age of this cohort was 58 (46 - 69) years; 50.4% were males and 64.4% black African. Dyslipidaemia was prevalent in 83.6% (n=209) of patients. A total of 169 (67.6%) patients were on LLT, and of these only 28 (16.6%) achieved the recommended low-density lipoprotein cholesterol (LDL-C) target. Of those not on LLT, 51 (63%) were eligible for LLT and almost all were classified as either very high risk (64.2%) or high risk (28.4%) for ASCVD. Of those on LLT, all were on statin therapy, of which simvastatin at a mean dose of 20 mg daily was the most commonly prescribed LLT. Conclusion. This cohort comprised a large proportion of patients classified as high or very high risk for ASCVD. Despite this, the use of LLT was inadequate, and <20% of patients were at target LDL-C levels. These data suggest a greater need for awareness of initiating LLT to achieve recommended target LDL-C levels in patients with CKD.
format Article
id doaj-art-3471df1bf47143ae813189720597b4c3
institution Kabale University
issn 0256-9574
2078-5135
language English
publishDate 2023-11-01
publisher South African Medical Association
record_format Article
series South African Medical Journal
spelling doaj-art-3471df1bf47143ae813189720597b4c32025-02-10T12:26:40ZengSouth African Medical AssociationSouth African Medical Journal0256-95742078-51352023-11-011131110.7196/SAMJ.2023.v113i11.1089Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factorM R Essop0F Seedat1F J Raal2Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaDepartment of Internal Medicine and Division of Endocrinology, Faculty of Health Sciences, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South AfricaDepartment of Internal Medicine and Division of Endocrinology, Faculty of Health Sciences, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa Background. Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD). In addition, CKD itself is a coronary artery disease equivalent due to its atherogenic potential. Despite the role of CKD in ASCVD and recommendations to control lipid levels aggressively, landmark lipid studies have often excluded patients with advanced CKD. Furthermore, there is a scarcity of data on the use and efficacy of lipid-lowering therapy (LLT) in those with CKD in South Africa (SA). Objectives. To determine the prevalence and control of dyslipidaemia in a cohort of SA patients with CKD. Methods. A retrospective, cross-sectional observational study of 250 patients with CKD attending the Charlotte Maxeke Johannesburg Academic Hospital renal clinic from 1 July 2019 to 31 July 2020 was carried out. Lipograms, the use of LLT and achievement of target lipid levels were examined. Results. The median (interquartile range) age of this cohort was 58 (46 - 69) years; 50.4% were males and 64.4% black African. Dyslipidaemia was prevalent in 83.6% (n=209) of patients. A total of 169 (67.6%) patients were on LLT, and of these only 28 (16.6%) achieved the recommended low-density lipoprotein cholesterol (LDL-C) target. Of those not on LLT, 51 (63%) were eligible for LLT and almost all were classified as either very high risk (64.2%) or high risk (28.4%) for ASCVD. Of those on LLT, all were on statin therapy, of which simvastatin at a mean dose of 20 mg daily was the most commonly prescribed LLT. Conclusion. This cohort comprised a large proportion of patients classified as high or very high risk for ASCVD. Despite this, the use of LLT was inadequate, and <20% of patients were at target LDL-C levels. These data suggest a greater need for awareness of initiating LLT to achieve recommended target LDL-C levels in patients with CKD. https://samajournals.co.za/index.php/samj/article/view/1089chronic kidney diseaseDyslipidaemiacardiovascular diseaseSouth Africa
spellingShingle M R Essop
F Seedat
F J Raal
Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factor
South African Medical Journal
chronic kidney disease
Dyslipidaemia
cardiovascular disease
South Africa
title Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factor
title_full Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factor
title_fullStr Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factor
title_full_unstemmed Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factor
title_short Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factor
title_sort dyslipidaemia in patients with chronic kidney disease a neglected cardiovascular risk factor
topic chronic kidney disease
Dyslipidaemia
cardiovascular disease
South Africa
url https://samajournals.co.za/index.php/samj/article/view/1089
work_keys_str_mv AT mressop dyslipidaemiainpatientswithchronickidneydiseaseaneglectedcardiovascularriskfactor
AT fseedat dyslipidaemiainpatientswithchronickidneydiseaseaneglectedcardiovascularriskfactor
AT fjraal dyslipidaemiainpatientswithchronickidneydiseaseaneglectedcardiovascularriskfactor